Immune checkpoint inhibitors for the management of advanced non-small-cell lung carcinoma: a meta-analysis

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Advanced non-small-cell lung cancer (NSCLC) presents significant treatment challenges.
• Programmed cell death-1/cell death-ligand 1 (PD-1/PD-L1) inhibitors represent a novel therapeutic strategy.
• Optimizing the efficacy and safety of PD-1/PD-L1 inhibitors is crucial for NSCLC management.

Purpose of the Study:

• To conduct a meta-analysis assessing the safety and efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC.
• To identify factors influencing treatment response and adverse events.
• To compare the outcomes of PD-1/PD-L1 inhibitors with traditional chemotherapy.

Main Methods:

• Meta-analysis of 17 clinical trials involving anti-PD-1/PD-L1 therapies for NSCLC.
• Calculation of pooled hazard ratios for overall survival (OS) and progression-free survival (PFS).
• Calculation of pooled odds ratios (ORs) for objective response rate (ORR) and adverse effects using Review Manager 5.3.

Main Results:

• PD-1/PD-L1 inhibitors significantly improved OS (HR 0.69) and PFS (HR 0.74).
• Objective response rates were significantly higher with PD-1/PD-L1 inhibitors (OR 1.78), especially in PD-L1 positive tumors (OR 2.48).
• A favorable safety profile was observed, with lower rates of treatment-related adverse effects (OR 0.33 for any, OR 0.30 for grade 3-5).

Conclusions:

• PD-1/PD-L1 immunotherapy offers superior efficacy in terms of ORR, OS, and PFS for advanced NSCLC compared to chemotherapy.
• The safety profile of PD-1/PD-L1 inhibitors is tolerable, supporting their use in clinical practice.
• Further subgroup analysis indicated dose and PD-L1 expression may influence treatment outcomes.